Articles tagged with Cancer
A NIH-led study identified key factors driving tumor evolution and influence outcomes in lung cancer, revealing a previously unknown origin of aggressive tumors associated with the ID2 mutational signature linked to LINE-1 reactivation. Major driver gene mutations also influenced tumor evolutionary trajectories.
Researchers used CRISPR technologies to discover previously unannotated DNA stretches in the 'dark genome', which control cell response to mechanical properties of their environment. This work could lead to new therapeutic targets for illnesses involving changes to tissue mechanics, including fibrosis and cancer.
A Stanford Medicine-led study reveals that a signaling pathway controls the immune response, allowing researchers to potentially treat various diseases. The research focuses on peripheral immune tolerance, which prevents inappropriate attacks on healthy tissue.
A case report describes a woman with radiation-induced cellular changes in her Pap smear that mimicked cancer recurrence. The study emphasizes the importance of recognizing these changes to prevent misdiagnosis and unnecessary medical procedures.
A new oral endocrine therapy, giredestrant, has been shown to significantly lower the risk of breast cancer recurrence in early-stage HR-positive/HER2-negative patients. In a large clinical trial, patients treated with giredestrant were 30% less likely to have invasive disease recur or progress.
Researchers have developed an AI-driven method to uncover genetic interactions driving cancer progression. The approach highlights complex interplay between genes allowing malignant cells to gain momentum and reveals previously hidden cancer drivers.
A study by Van Andel Institute scientists found that reducing calorie intake helps cancer-fighting immune cells do their jobs more effectively. The researchers discovered that a low-fat, high-protein diet given once a day promotes the formation of ketones, which act as a cellular fuel for T cells to become more effective tumor fighters.
Researchers at OIST have discovered that certain cancers can 'lose their sense of time' to avoid cellular stress responses. The study highlights the role of USP28 in stabilizing p53, a known tumor suppressor, and how mutations in this protein can disrupt its function.
Veterans and first responders face elevated risk of cancer due to occupational exposures, such as firefighting. Experts call for better access to high-quality cancer prevention, screening, and treatment, including presumptive laws and expanded support services.
A cohort study found that older Medicare beneficiaries with common metastatic cancers had a mean of 40 to 62 health care contact days after diagnosis. Health care contact days increased from 2008 to 2019, highlighting the need for oncology teams to discuss expected burdens when developing care goals and treatment plans.
Researchers at UCLA Health Jonsson Comprehensive Cancer Center have identified a small molecule that can inhibit cancer-driving protein IGF2BP3, slowing leukemia growth and triggering cancer cell death. The discovery could lead to new treatments for leukemia and other hard-to-treat cancers.
The MUTE-Seq method detects rare cancer mutations at exceptionally low frequencies, enriching circulating tumor DNA and improving detection accuracy. It increases variant allele frequencies by tens of times, enabling detection of mutations present at 0.005% or lower.
A new clinical trial suggests that combining bispecific antibodies and antibody-drug conjugates with CAR T-cell therapy may significantly enhance one-year progression-free survival for people with aggressive lymphoma. The study found that 90% of patients were in complete remission at day 90, and about 80% remained in remission at one y...
Researchers have discovered triaptosis, a novel cell death mechanism that selectively targets and kills cancer cells, offering a new hope in oncology. This process is mechanistically distinct from all previously known cell death pathways and holds considerable promise for combination with immunotherapy.
Researchers present promising new data from two ongoing studies of pivekimab sunirine targeting CD123 in treating two aggressive blood cancers, acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm (BPDCN). The triplet regimen including pivekimab sunirine showed high response rates and enabled stem cell transpla...
A study finds that most people trust doctors more than AI for health diagnoses, but have a positive view of AI's potential in cancer diagnosis. The research used two nationally representative surveys to assess public attitudes toward AI in healthcare, including trust, understanding, and excitement.
A new study identifies a practical and powerful prognostic marker that can help clinicians tailor treatment strategies to improve survival for patients with aggressive T-cell lymphoma. Researchers found that patients who relapse within 12 months of initial therapy have a dramatically declining chance of survival, making targeted therap...
Researchers discover that CDT1 overexpression suppresses DNA replication and induces DNA damage, potentially leading to genetic mutations and cancer. The study provides molecular insights into the role of CDT1 in cancer development.
Patients with lower-risk myelodysplastic syndromes experienced strong responses with fewer side effects when treated with a five-day azacitidine compared to shorter durations. The five-day regimen offered the best balance of safety and efficacy, demonstrating improved event-free survival and overall survival.
A new computational tool has discovered a previously unknown protein pathway that triggers the death of blood cancer cells when blocked. This finding could lead to new treatments and improved survival rates for patients with aggressive acute myeloid leukaemia (AML).
Researchers developed an antibody therapy called 77A that targets HSP70, a heat shock protein helping tumors evade the immune system. The treatment showed strong antitumor effects by enhancing immune cell activity in laboratory models of multiple cancer types.
Researchers mapped NBCn1's structure-function properties to understand how breast cancer cells thrive in hostile environments. The study provides insights into the protein's dynamics and ion transport pathways, paving the way for designing drugs that target this transporter.
MIT chemists successfully synthesized verticillin A, a fungal compound that has shown potential as an anticancer agent. The researchers then generated derivatives of the compound and tested them against pediatric brain tumors, finding that some were effective against cancer cells with high levels of EZHIP protein.
Researchers at CU Anschutz have discovered a novel therapy combination to offer new hope to ovarian cancer patients who do not respond to existing treatments. The combination of a PARP inhibitor and SM08502 boosts the effectiveness of treatment, even for patients resistant to PARP inhibitors.
Researchers found that sudden cardiac death (SCD) among colorectal cancer patients decreased overall, but disparities remained based on age, sex, and geographic location. The study highlights the need for tailored heart monitoring and care strategies for cancer patients, particularly in underserved groups.
Researchers have developed a simple urine test that can effectively diagnose and stage bladder cancer using cell-free DNA fragmentation analysis. The study found that specific patterns of cfDNA fragmentation can identify muscle-invasive bladder cancer with excellent specificity and predictive value.
Researchers at UCLA present several new studies on emerging blood-based surveillance tools, new approaches to predicting treatment response, and tailoring therapies across the disease spectrum for patients with breast cancer. The findings highlight the potential of precision medicine in improving quality of life.
The ACRF MATRIX Centre will enable researchers to study cancer cells and their surrounding environment with unprecedented molecular resolution. This will help develop combination therapies targeting both cancer cells and the microenvironment.
Renuka Iyer, a leading oncologist with extensive experience in cancer care and research, has been appointed as the new Chief Medical Officer of the National Comprehensive Cancer Network. She will oversee the development of evidence-based guidelines for cancer prevention and treatment.
A new remote group intervention, CRAFT-G, combining cognitive training and occupational-therapy-based strategies, showed high satisfaction and clinically meaningful improvements in daily functioning among cancer survivors. The program proved to be accessible and effective in helping survivors manage 'chemobrain' and reclaim everyday life.
A survey study found that overall trust in scientists as sources of cancer information is high, but ideologically diverse. The results suggest the need for tailored messaging and trusted messengers to reach diverse audiences with evidence-based cancer information.
A new organ-on-a-chip platform recapitulates age-dependent immune responses, allowing for more accurate testing of cancer vaccines in older adults. The platform reveals functional differences in immune responses between young and old lymphocytes, which are not detectable with traditional 2D cultures.
A new study developed an antibody that blocks several ways TNBC cells survive, grow, and evade the immune system. The antibody suppressed primary tumor growth and reenergized cancer-fighting immune cells, including T-cells and macrophages, in preclinical models.
A recent study by UCLA Health investigators found that mental health conditions significantly raise the likelihood of developing liver cancer among US veterans living with cirrhosis and hepatitis C. The study suggests that these disorders limit access to hepatitis C care, reducing the chance of a cure.
Researchers at the University of Plymouth will receive a £2.8 million funding boost to accelerate new treatments for low-grade brain tumors. The center aims to deepen understanding and translate knowledge into life-changing therapies.
Scientists at Penn Vet have identified two genes, Ctnna1 and Bcl2l13, that suppress metastasis in preclinical models of colorectal cancer. These findings could lead to better treatments and therapies for patients with metastatic disease.
Researchers at Rice University have developed a way to make serum markers more sensitive by editing them inside the bloodstream, enabling clearer observation of gene-expression changes in the brain. This approach could lead to more precise diagnostic capabilities using simple blood tests.
Researchers from Mass General Brigham Cancer Institute present promising new treatment options for acute myeloid leukemia, autoimmune bleeding disorders, and multiple myeloma. The studies show improved event-free survival, higher overall response rates, and better quality of life for patients treated with novel therapies.
Fred Hutch experts will present CAR-T access expansion, new AML treatment strategies, and the impact of climate on cancer. Experts discuss optimizing maintenance therapy using MRD-directed approaches for high-risk AML patients and evaluating the safety & efficacy of combining PIVEK with FLAG-IDA for adults with untreated AML.
Research highlights the connection between fungi and cancer, revealing that fungal microbiome can promote tumour progression and activate immunosuppressive pathways. Modulating the fungal microbiome may enhance antitumour immunity, with preliminary validation from preclinical and clinical trials.
Robotic exoskeletons enhance cancer patients' mobility, muscle strength, and gait training while providing personalized support and real-time feedback. This innovation integrates traditional therapies, nutritional support, and cognitive behavioral therapy to improve therapeutic outcomes.
This study explores the immune and molecular basis of lung cancer complicated by pulmonary tuberculosis, identifying diagnostic biomarkers through transcriptome analysis. Key findings include increased CD4+ T cells, NK cells, and specific gene expressions, providing a validated four-gene diagnostic signature for external evaluation.
A UTEP research team found that Claudin-4, a protein increasing in ovarian cancer, may help tumors survive and hide from the immune system. Targeting Claudin-4 with a peptide and PARP inhibitor slows tumor growth and enhances the immune system's ability to fight cancer.
A recent study found that more adolescents and young adults (AYAs) with cancer received palliative care between 2018 and 2022 compared to previous studies. However, the researchers also noted challenges in providing quality palliative care, including stigma and high-intensity end-of-life care.
A new study in Molecular Cell reveals that cellular aging is controlled by the ATM kinase response to withered telomeres. Cells grown under low oxygen conditions are more tolerant of short telomeres, while high oxygen accelerates cellular aging due to hyperactive ATM.
The updated 2025 American Society of Hematology guidelines recommend that most older adults with acute myeloid leukemia (AML) receive treatment, including gentler chemotherapy regimens and targeted therapies. The guidelines aim to provide more personalized and effective care for this patient population.
The study analyzed global data from 1990 to 2021, finding that GI cancer risks peak between ages 40-64 and differ by sex, socioeconomic status, and geography. Colorectal cancer has the highest incidence risk, while stomach cancer demonstrates the highest mortality risk.
Researchers found that FOLFIRINOX improved progression-free and overall survival in patients with advanced biliary tract cancer. The treatment may offer a benefit as a second-line option after first-line chemotherapy failure, but toxicity remains a concern.
The study reveals a significant burden of metastatic disease in adolescents and young adults with cancer. The findings expand knowledge on metastatic recurrences, improving care for adolescent and young adult survivors.
The new system can reveal early cancers, lung disease, hidden material defects and changes in porosity without multiple exposures or complex mechanical movement. This method produces low-dose and faster images, lowering patients' radiation dose and making clinical translation feasible.
The SISAQOL-IMI consortium has published key guidelines for patient-reported outcomes in cancer clinical trials, providing a harmonised framework for designing, analysing, and interpreting PRO data. The new online toolkit offers practical resources to support implementation across the research and policy landscape.
Zanidatamab demonstrated significant efficacy in patients with HER2-positive biliary tract cancer, achieving response rates of up to 51.6% and improving symptoms such as pain levels. The trial's results support the emerging role of zanidatamab as a treatment paradigm for this rare and aggressive cancer.
Researchers at the University of Virginia Health System have developed a new treatment for acute myeloid leukemia, a deadly form of blood cancer. The FDA-approved medication works by disrupting cellular protein interactions that drive leukemia cell growth and survival, offering patients a potential cure.
A study published in JAMA Oncology found that shorter courses of androgen deprivation therapy can effectively control prostate cancer without increasing risks. The ideal duration of ADT depends on cancer risk, allowing for more personalized treatment plans.
A global survey led by UC Irvine researchers found that 70% of oncology professionals use or recommend integrative approaches to manage cancer symptoms. However, these services remain underused due to cost, lack of insurance coverage, and limited training opportunities, particularly in low-income countries.
The report emphasizes the importance of pairing research with policy partners and investing in mentorship and career advancement of Latino scientists and students. It also calls for implementing evidence-based practices, using telemedicine and AI equitably, and designing trauma-informed interventions that fit Latino family life.
A new review connects gut microbiome imbalances to obesity, metabolic syndrome, and colorectal cancer, highlighting the potential for diet and microbiome-based treatments. The study also explores racial and socioeconomic disparities in microbiome-related diseases, emphasizing the need for inclusive prevention strategies.
Researchers have discovered that rhesus macaques shed TIGIT from immune cell surfaces when exposed to plasmin, a natural enzyme involved in blood clot breakdown. This creates a soluble form of TIGIT that can still bind anti-TIGIT monoclonal antibodies, potentially leading to misleading safety and efficacy data for human trials.
Researchers at the University of York have discovered a way to harness radiation from particle accelerator beam dumps to produce medical isotopes used in cancer diagnosis and treatment. Copper-67 is a rare isotope with limited global supplies, but this method could generate it without affecting main physics experiments.
A novel liver cancer vaccine has achieved responses in a rare disease affecting children and young adults, with 75% of patients experiencing disease control. Three patients are now believed to be cancer-free after receiving the therapy, including a 13-year-old patient who achieved a nearly complete response.